This filing is part of the company’s quarterly result. Read the full results article, with every figure explained →
Consolidated Q2 FY27 revenue and profit surge year on year
SAIPARENT · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 8.5 pts less than Nifty Microcap 250 and 7.3 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Consolidated Q2 FY27 revenue from operations was Rs 196.1 crore versus Rs 54.9 crore in Q2 FY26, while profit after tax rose from Rs 7.2 crore to Rs 10.5 crore. Revenue grew 257% and profit 46% year on year. Profit before interest, tax, depreciation and amortisation margin fell from 23.3% to 21.1%. The comparison is not like-for-like because Noumed was consolidated from November 12, 2025. Two acquisitions closed; Unit III capacity rose 81%.
Headline growth may support the stock, but the uneven Noumed comparison, margin pressure and higher depreciation could limit near-term gains.
| Q2 FY27 | Year ago | Change | |
|---|---|---|---|
| Revenue | ₹194.9 Cr | — | — |
| Operating profit | ₹6.17 Cr | — | — |
| Profit after tax | ₹10.51 Cr | — | — |
| EBITDA margin | 20.6% | — | — |
From the company's XBRL filing, not from the text above. Operating profit = profit before tax − exceptional items − other income. EBITDA = profit before tax + finance costs + depreciation − other income. No year-ago figures on this basis yet, so no comparison.